At a glance
ClinicalIndex Comparison Record- ✓High-grade dysplasia of the esophagus requiring esophagectomy OR esophageal cancer stage T1-T3, N0-N1 requiring esophagectomy
- ✓Pathological confirmation of cancer or high-grade dysplasia by biopsy
- ✓CT scan of chest and abdomen within 6 weeks prior to registration
- ✓Stomach available for conduit
- ✕Cancer extending into the stomach more than 20%
- ✕Prior anti-reflux or gastric operations
- ✕Prior right thoracotomy
- ✕Prior major neck operation other than removal of superficial skin lesion
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study
In Brief
A Phase 2 clinical trial evaluating Minimally invasive esophagectomy (MIE) for Esophageal Cancer. Completed, enrolled 110 participants across 41 sites.
Detailed Summary
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery. PURPOSE: This phase II trial is studying how well laparoscopic-assisted surgery and video-assisted thoracoscopy work in treating patients who are undergoing esophagectomy for high-grade dysplasia of the esophagus or stage I, stage II, or stage III esophageal cancer.
Study Details
Timeline
Interventions
Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.